Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
- Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir -
- 将两年一次注射剂Lenacapavir用于艾滋病预防的后期结果
- Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development Programs -
- 在治疗、治愈研究和开发计划全面推进和以人为中心的方法方面取得进展
- Key Initiatives Demonstrate Commitment to Collaboration to Help End the HIV Epidemic Worldwide -
- 重要举措体现了合作致力于帮助全球终结艾滋病流行的承诺
Gilead Sciences, Inc. (NASDAQ:GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany, and virtually, from July 22-26. As the leading innovator in HIV, Gilead will share new data from its research and development programs and Gilead-supported collaborations that unite leading scientific innovation and partnership aimed at ending the HIV epidemic.
吉利德科学公司（纳斯达克：GILD）今天宣布了其即将到来的第25届国际艾滋病会议（AIDS 2024）计划，该会议将于7月22日至26日在德国慕尼黑和虚拟线上举行。作为艾滋病领先创新者，吉利德将分享自己的研究开发计划和吉利德支持的合作方面的新数据，这些合作团结了领先的科学创新和伙伴关系，旨在终结艾滋病疫情。